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Abstract
Background: Cognitive impairment affects approximately 50% of people with amyotrophic lateral sclerosis (ALS). Research
has indicated that impairment may worsen with disease progression. The Edinburgh Cognitive and Behavioural ALS
Screen (ECAS) was designed to measure neuropsychological functioning in ALS, with its alternate forms (ECAS-A, B, and
C) allowing for serial assessment over time. Objective: The aim of the present study was to establish reliable change scores
for the alternate forms of the ECAS, and to explore practice effects and test-retest reliability of the ECAS’s alternate forms.
Method: Eighty healthy participants were recruited, with 57 completing two and 51 completing three assessments.
Participants were administered alternate versions of the ECAS serially (A-B-C) at four-month intervals. Intra-class
correlation analysis was employed to explore test-retest reliability, while analysis of variance was used to examine the
presence of practice effects. Reliable change indices (RCI) and regression-based methods were utilized to establish change
scores for the ECAS alternate forms. Results: Test-retest reliability was excellent for ALS Specific, ALS Non-Specific, and
ECAS Total scores of the combined ECAS A, B, and C (all4.90). No significant practice effects were observed over the
three testing sessions. RCI and regression-based methods produced similar change scores. Conclusion: The alternate forms
of the ECAS possess excellent test-retest reliability in a healthy control sample, with no significant practice effects. The use
of conservative RCI scores is recommended. Therefore, a change of 8, 4, and 9 for ALS Specific, ALS Non-Specific,
and ECAS Total score is required for reliable change.
Keywords: Cognition, ECAS, alternate forms, test reliability, practice
Introduction
Cognitive and behavioural symptoms affect approxi-
mately 50% of patients with amyotrophic lateral
sclerosis (ALS), of whom 15% develop FTD
(frontotemporal dementia) and the two form a
spectrum disease. Executive dysfunction, language
dysfunction, and social cognitive deficits are com-
monly reported (1–3). The presence of cognitive
and behavioural symptoms in ALS can precede
motor symptoms (4), have been associated with
reduced survival (5,6), disengagement with life
prolonging interventions (7), and increased care-
giver burden (8,9). Neuropsychological status has
additional implications for end-of-life care planning,
capacity to consent, and powers of attorney (2).
Thus, timely and accurate knowledge of patients’
cognitive and behavioural status is vital for providing
person-centred care.
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The Edinburgh Cognitive and Behavioural ALS
Screen (ECAS) was developed to offer a compre-
hensive screening tool to assess the cognitive and
behavioural status of patients with ALS (10).
The ECAS has been validated against full neuro-
psychological test batteries (11–16) and was
designed specifically for patients with ALS in that
it accommodates motor disability.
Cognitive decline over the course of the disease
(17), or in response to specific disease factors such
as respiratory insufficiency (18), has been suggested
and it is consequently important to monitor pro-
gression of cognitive symptoms. Howevert, repeated
assessment using neuropsychological tests may
result in improvement due to practice effects, i.e.
improvement in performance due to learning test
content, or test-taking strategies. For clinicians, it
can be difficult to interpret whether an observed
difference in test performance is due to true change
in the patient’s situation (recovery or decline) or
extraneous factors. Measurement error, regression
to the mean, and practice effects can produce or
exaggerate changes in performance between testing
sessions. Furthermore, demographic factors such as
age, education level, and baseline performance can
influence change in scores between testing sessions,
and therefore, obscure a patient’s true performance
variation (19). With regard to the ECAS, practice
effects have been demonstrated with healthy con-
trols in the executive, language, and memory
domains over six months, when using version A
for repeat assessments (20).
Recently, alternate forms of the ECAS have been
developed to accommodate the repeated assessment
of patients with ALS (21). The alternate forms of
the ECAS (the ECAS-B and ECAS-C) were
designed to retain the construct characteristics and
level of difficulty of the original ECAS-A while
reducing potential practice effects. The ECAS-B
and C have shown to be equivalent to the original
ECAS-A, and resistant to practice effects from
repeated administration (21). It has yet to be
determined what can be regarded as a meaningful
change on a case-by-case basis. Numerous methods
have been proposed to support the interpretation of
change scores on neuropsychological tests. Most
notably, clinicians have utilized reliable change
indices (RCI) and regression-based methods.
With regard to RCI methods, change in scores
for an individual patient is interpreted in the context
of normal healthy variation, such that an observed
change in a patient’s score needs to fall outside of
the standard error of healthy controls’ test-retest
variability (22). Numerous variations of the RCI
have been developed which adjust for factors such as
practice effects, and regression to the mean (23).
Conversely, regression-based methods employ
regression models to predict performance at
follow-up from initial test performance. Again,
significant differences between a patient’s predicted
and actual score are used to determine reliable
change. The regression-based method additionally
allows the inclusion of moderating variables such as
age and education, and controls for practice effects
and regression to the mean (24). RCI and regres-
sion-based methods allow clinicians to interpret
patients’ change scores or can provide a meaningful
interpretation or endpoint for clinical trials.
The aims of this study are: (1) to examine whether
practice effects are observed using the ECAS alter-
nate forms over clinically meaningful test-retest
intervals; (2) to determine test-retest reliability of
the ECAS-A-B-C over clinically meaningful inter-
vals; and (3) to compare common methods for
measuring reliable change in a patient’s ECAS
score across serially administered alternate versions.
Method
Participants
Eighty Irish and Scottish healthy adults were
recruited representative of the demographic charac-
teristics of ALS patients. Only those participants
who completed the ECAS at two or more time-
points were included in the present study.
Fifty-seven participants completed one follow-up
assessment, and 51 participants completed two
follow-up assessments. Exclusion criteria included:
a history of dyslexia or marked premorbid reading or
writing difficulties or a learning disability; non-
fluent English reading and writing abilities; history
of neurological conditions that could affect cogni-
tion such as major hemispheric stroke, traumatic
brain injury, and severe active epilepsy; alcohol and
drug dependencies; and having a known blood
relative with ALS. Participants were recruited
through a research volunteer panel and through
local community noticeboards. Non-blood relatives
of ALS patients were also recruited as control
participants. All participants provided informed
written consent and this research was approved by
the University of Edinburgh Psychology Research
Ethics Committee and the Beaumont Research
Ethics Committee. Participants’ travel costs asso-
ciated with participation were reimbursed.
Procedure
Participants were assessed every four months for
three occasions. The ECAS is an ALS-designed
measure of cognitive and behavioural functioning.
For the purposes of this study, the ECAS behav-
ioural interview was not included. The ECAS
consists of three versions (A-B-C) which were
designed to be administered serially. Each version
of the ECAS consists of 15 parallel tests, categorized
into five cognitive domains. Executive, language,
and verbal fluency domains are described as ALS
Specific functions, while the memory and
2 C. Crockford et al.
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visuospatial domains are described as ALS Non-
Specific. The ALS-Specific and ALS Non-Specific
domains combine to generate a measure of global
cognitive functioning, namely, the ECAS Total
score. At each assessment point, an alternate version
of the ECAS was administered such that the ECAS-
A was given at Time 1, the ECAS-B at Time 2, and
the ECAS-C at Time 3.
Statistical analysis
Statistical analyses were conducted using R 3.3.2.
Change scores were calculated for each time com-
parison by subtracting the baseline score from the
follow-up score, i.e. (Time 2 – Time 1, Time 3 –
Time 2, and Time 3 – Time 1). Welch t-tests were
used to compare change scores between centres to
ensure comparability. When data did not meet
assumptions of normality, Mann-Whitney U-tests
were employed. In all cases, Time 1 is synonymous
with ECAS-A, Time 2 with ECAS-B, and Time 3
with ECAS-C.
Test-retest reliability: of the alternate forms of the
ECAS (A-B-C) was examined using intraclass cor-
relation coefficients (ICC) with mean-rating abso-
lute agreement two-way random effects models.
ICC coefficients were calculated for the component
(language, fluency, executive, memory, visuospatial)
and composite (ALS Specific, ALS Non-Specific,
ECAS Total) domains of the ECAS.
Practice effects: were explored using one-way
repeated measures analysis of variance models
(ANOVA) to examine the presence of a main
effect of Time. Repeated measures ANOVAs are
limited to balanced designs and only those partici-
pants who completed all three time-points were
included in this analysis.
Change indices: were calculated using four types
of model: two regression-based methods and two
reliable change index (RCI) methods. Each method
corrects for slightly different moderating effects. The
RCI JT method accounts for measurement error,
while the Chelune method additionally accounts for
practice effects. While significant practice effects in
using alternate versions of the ECAS have not
previously been found (21), small improvements
may be present which might not reach statistical
significance. The simple regression method incorp-
orates corrections for regression to the mean,
whereby individuals who perform in the extremes
tend to converge on the group mean at follow-up.
Finally, the multiple regression method allows for
the incorporation of potential moderating variables
such as age and education that may influence change
over time. Given the higher sensitivity of the ALS
Specific, ALS Non-Specific, and ECAS Total scores
to cognitive impairment against a full neuropsycho-
logical battery (13), change score analysis was
conducted for these composite domains.
Method 1: RCI (JT method)
The first RCI model calculated was the Jacobson
and Truax method (JT method) (25), which
accounts for measurement error. The JT method is
calculated as the difference between Time 2 and
Time 1 divided by the standard error of difference
ðSEdiff Þ between these two time-points. The standard
error of the difference is derived from the standard
error of the measurement ðSEmÞ such that
SEdiff ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ðSEmÞ2
q
. The standard error of the meas-
urement ðSEmÞ is calculated with the equation
SEm ¼ s1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 rxx
p
, where s1 is the standard deviation
of the Time 1 ECAS (i.e. for ECAS-B, the
preceding version is ECAS-A, and for ECAS-C
the preceding version is ECAS-B) and rxx is the test-
retest reliability coefficient between these two ECAS
forms. Therefore, the RCI equation using the JT
method is calculated with the formula:
RCI ¼ x2  x1
SEdiff
Reliable change is defined by values larger than
1.645 (two-tailed 90% confidence interval). The
formula was then restructured to calculate the upper
and lower ‘thresholds’ of reliable change ðXÞ i.e. the
number of points increase/decrease required
between two testing sessions, which constitutes a
reliable change. Therefore, the equation was
restructured as:
DX ¼ 1:645ðSEdiff Þ
Method 2: RCI (chelune method)
The second RCI method employed is the Chelune
method (26), which corrects for measurement error
and practice effects. While the alternate versions of
the ECAS were developed to account for practice
effects, it is possible that small non-significant
improvements continue to exist. Additionally, the
accounting for practice effects here may help to
account for any small but non-significant differences
in difficulty present in the alternate versions. The
Chelune method is similar to the JT method, taking
the form of:
RCI ¼ ðx2  x1Þ  ð
X2  X1Þ
SEdiff
Here, the denominator is again the standard
error of the difference SEdiff (i.e.
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ðSEmÞ2
q
).
However, the Chelune method adds a constant as
to the numerator to account for systematic changes
in performance such as practice effects. This is
achieved by calculating the mean difference in
performance between Time 2 and Time 1
ðX2  X1Þ and subtracting this from an individual’s
Measuring reliable change in congnition using the ECAS 3
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change score. As before, this equation was restruc-
tured to solve for X resulting in:
DX ¼ X2  X1ð Þ  1:645ðSEdiff Þ
Method 3: Simple linear regression
The first regression-based method employs a simple
linear regression model that predicts follow-up
performance based on the preceding performance.
First, a patient’s predicted Time 2 score is calcu-
lated using the basic regression equation:
X^ ¼ X þ C
Where X^ is an individual’s predicted Time 2
score,  is the beta coefficient for the predictor in
the model, X is the Time 1 score, and C is the
intercept estimate of the model. Next, the discrep-
ancy between the observed Time 2 score and the
predicted Time 2 score is calculated and referred to
as the residual (i.e. Time 2 – predicted Time 2). To
extract a change index, this residual is then divided
by the residual standard error (or standard error of
the estimate; SEE). When values of the residual
divided by the SEE are greater than 1.645 (two-
tailed 90% confidence interval) a reliable change
can be determined. To determine reliable change
‘thresholds’, the equation is restructured to solve for
the residual such that:
ðX  X^Þ ¼ 1:645ðSEEÞ
Where ðX  X^Þ is the difference between the
observed score and the estimated score. The same
procedure is used for predicting Time 3 perform-
ance from Time 2.
Method 4: Multiple linear regression
The second regression-based method is a multiple
linear regression model to explore whether age,
education, sex, preceding performance, or testing
interval affects the model’s prediction. Potential
predictors were selected based on their correlation
with the respective outcome variable (i.e. ALS
Specific, ALS Non-Specific, or ECAS Total
scores). A relationship with sex was explored using
Mann-Whitney U-tests. Variables of interest were
entered into each model in a single block and only
retained if their individual contribution to the model
was significant (i.e. backward elimination).
Significantly influential cases were removed based
on diagnostic plots. Multiple regression equations,
similar to simple linear regression equations, take
the form of:
X^ ¼ 1X1 þ 2X2 . . .þ . . .jXj þ C
Where 1 is the coefficient of the first variable of
interest, X1 is the observed score for the first
variable, 2 is the coefficient for the second variable,
and so on to the Jth variable. Again, this equation is
restructured to solve for ðX  X^Þ such that:
ðX  X^Þ ¼ 1:645ðSEEÞ
Results
Fifty-seven participants completed two or more
time-points and were included in the present
study. Participants were 61.40% male (n¼ 35)
with a mean age of 62.32 13.36 years and
14.87 3.19 years of education. Mean test-retest
intervals were 4.30 0.66 months and 3.99 0.54
months for T1 to T2, and for T2 to T3, respectively.
Mean change scores were calculated for Time 1 to
Time 2, Time 2 to Time 3, and Time 1 to Time 3.
No significant differences were observed in mean
change scores, nor in age, gender, or education
between Irish and Scottish participants (all p40.05)
indicating comparability.
Practice effects
Mean test performance for the subdomains of the
ECAS and its alternate versions are displayed in
Table 1. Mean performance for all cognitive sub-
domains (language, executive, fluency, memory, and
visuospatial) are analogous across time-points, such
that no mean difference exceeded 1 point. The
resulting ANOVA models produced no significant
main effect for executive functions (F(2,100)¼ 1.43,
p¼ 0.24), fluency (F(2,100)¼ .25, p¼ 0.780), or
memory (F(2,100)¼ 1.04, p¼ 0.358). Additionally,
no main effect was observed for the composite ALS
Specific (F(2,100)¼ .852, p¼ 0.43), ALS Non-
Specific (F(2,100)¼ .838, p¼ 0.435), nor ECAS
Total (F(2,100)¼ .428, p¼ 0.653). Due to ceiling
Table 1. Mean scores and standard deviations for the ECAS-A, ECAS-B, and ECAS-C.
ECAS-A ECAS-B ECAS-C
ALS Specific (max 100) 85.65 8.56 86.39 8.55 86.209.49
Language (max 28) 27.14 1.87 26.74 2.09 26.761.89
Fluency (max 24) 19.61 2.71 19.82 2.43 19.694.22
Executive (max 48) 38.89 5.59 39.82 5.37 39.755.68
ALS Non-Specific (max 36) 30.14 3.73 29.89 3.66 30.413.11
Memory (max 24) 18.46 3.43 18.51 3.13 18.882.89
Visuospatial (max 12) 11.68 0.74 11.39 1.00 11.530.70
ECAS Total (max 136) 115.79 11.26 116.28 11.38 116.6111.87
4 C. Crockford et al.
D
ow
nl
oa
de
d 
by
 [T
he
 U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 05
:06
 15
 D
ec
em
be
r 2
01
7 
effects and thus the presence of ties in the language
and visuospatial subtests, formal analysis was not
conducted. However, given the similarity in mean
scores and the lack of significant differences for their
composite domains, a lack of observable practice
effects may be assumed. Therefore, no evidence of
practice effects was found for the repeated assess-
ment using the ECAS alternate versions (A-B-C)
over clinically relevant test-retest intervals of three to
four months.
Test-retest reliability
Two-way absolute agreement mixed effects ICC
models were generated for each subdomain of the
ECAS (see Supplementary materials). Test-retest
reliability was good for the majority of subdomains
(i.e.4.70). The only subtest to fall below .70 was
the visuospatial domain. However, a lack of vari-
ability due to participants reaching ceiling (i.e. over
50% scoring 12 points for each version of the
ECAS) will exacerbate small differences in perform-
ance rendering this result unreliable (27). With
regard to the ALS Specific, ALS Non-Specific, and
ECAS Total scores, test-retest reliability was
excellent.
Change indices
RCI method: Methods 1 and 2
Reliable change indices (RCI) were calculated for
ALS Specific, ALS Non-Specific, and ECAS Total
score using the Jacobson and Truax method (JT
method) (25) and the Chelune method (26).
Thresholds for reliable change are displayed in
Table 2, in addition to recommended clinical
thresholds. Data used to calculate RCI thresholds
are available in Supplementary Table 1. These
thresholds provide the number of points increase
required to determine a reliable improvement in
cognitive performance and the number of points
decrease required to determine a reliable decline in
functioning. For example, using the JT method, a
drop of 8.23 points or greater in ECAS Total score
between the ECAS-A and ECAS-B is required for a
reliable decline, while an increase of 8.23 points
constitutes a reliable improvement. By comparison,
using the Chelune method a drop of 7.74 points is
required for a reliable decline, or an increase of 8.72
points for a reliable improvement due to the
incorporation of practice effects.
Method 3: Simple linear regression
Simple linear regression models were built to predict
follow-up scores based on previous performance.
Table 3 provides data for calculating predicted
ECAS-B performance from ECAS-A, and for pre-
dicting ECAS-C from ECAS-B using the equation
X^ ¼ X þ C. This predicted score can then be
converted into a change index with 1.645 con-
stituting a reliable deviation for predicted perform-
ance. Alternatively, the column X  X^ in Table 3
provides upper and lower thresholds calculated
asðX  X^Þ ¼ 1:645ðSEEÞ.
Method 4: Multiple linear regression
Variables of interest were explored as potential
moderating factors in multiple regression models
using correlational analysis. For the ECAS-B, edu-
cation level significantly correlated with ALS
Specific (r¼ .42, p¼ 0.002), ALS Non-Specific
(r¼ .49, p50.001), and ECAS Total (r¼ .47,
p50.001) scores. Age at testing and test-retest
interval did not significantly correlate with ECAS-
Table 2. RCI thresholds for the ECAS-A, ECAS-B, and ECAS-C.
JT method Chelune method
ALS
Specific DX
ALS
Non-Specific DX
ECAS Total
DX
ALS Specific
DX
ALS Non-Specific
DX
ECAS Total
DX
ECAS-A to ECAS-B  7.23  3.35  8.23 6.50547.97 3.60543.11 7.74548.72
ECAS-B to ECAS-C  6.44  3.19 7.18 6.63546.25 2.68543.70 6.86547.51
ECAS-A to ECAS-C  6.02  2.97  6.64 5.47546.56 2.70543.24 5.82547.46
Recommended for clinical use  8  4  9
DX is the change in score required to be considered significant. The Chelune method results in different upper and lower thresholds due to
its subtraction of a constant.
Table 3. Simple linear regression equations for predicting ECAS-
B and ECAS-C performance.
R2 SEE C (ECAS-A) X  X^
Predicting ECAS-B from ECAS-A
ALS Specific 0.398 5.29 34.18 0.613 8.70
ALS Non-Specific 0.297 2.25 15.31 0.490 3.70
ECAS Total 0.448 6.23 41.62 0.648 10.24
R2 SEE C (ECAS-B) X  X^
Predicting ECAS-C from ECAS-B
ALS Specific 0.700 5.30 34.18 0.938 8.72
ALS Non-Specific 0.597 2.00 11.60 0.628 3.29
ECAS Total 0.741 6.12 14.78 0.872 10.07
R2 is the multiple R2. SEE is the residual standard error, C is the
intercept,  is the beta coefficient associated with the subscript
ECAS, X  X^ is the residual (i.e. the difference between the
model predicted score and the observed score). The X  X^
column indicates the number of points difference required
between observed and estimated score to determine reliable
difference – this is calculated as 1.645*(SEE).
Measuring reliable change in congnition using the ECAS 5
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B performance, and no significant effect of sex was
observed. For the ECAS-C, education level again
significantly correlated with ALS Specific (r¼ .40,
p¼ 0.002), ALS Non- Specific (r¼ .31, p¼ 0.02),
and ECAS Total (r¼ .40, p¼ 0.002) scores. The
ALS Non-Specific functions of ECAS-C signifi-
cantly correlated with age (r¼.32, p¼ 0.02) and
test-retest interval (r¼.30, p¼ 0.03). Additionally,
a marginally significant Mann-Whitney U-test was
observed for sex and ALS Specific functions of
ECAS-C (W¼ 207, p¼ 0.047). While these vari-
ables are retained for the regression models, the
significant correlations with age, sex, and test-retest
interval do not survive Holm correction for multiple
comparisons (all p40.05).
Significant variables were entered into regression
models in a single block and individual variables
were only retained once their contribution to the
model remained significant. For the multiple regres-
sion models, the variance inflation factor for the
predictors did not exceed 2. Table 4 displays the
results of these models. For the prediction of ECAS-
B, education is retained in the model for ALS
Specific and ECAS Total scores. For the ECAS-C,
education significantly added to the model for ALS
Non-Specific scores. No other variables were
retained in the final multiple regression models.
Additional models were generated to predict ECAS-
C from the combined performance on ECAS-A and
ECAS-B. As with the previous multiple regression
models, variables of interest were correlated with,
and regressed onto, the ECAS-C. However, in this
instance, the only variable retained is that of age on
ALS Non-Specific.
Example data
A 62-years-old male limb-onset ALS patient with
10.5 years of education was assessed at two time-
points, with a four-month interval between Time 1
and Time 2. The patient had no behavioural or
respiratory symptoms at either time-point. For the
ECAS total, the patient scored 108 on the ECAS-A,
and 96 on the ECAS-B. This resulted in change
scores of 12 which falls below the RCI threshold
for significant decline by both the JT method and
the Chelune method, and the recommended clinical
thresholds (Table 2).
Using the simple regression-based method,
this patient’s predicted ECAS-B score is calculated
using the equation X^ ¼ X þ C, where in this case
X^ ¼ ð:648Þð108Þ þ 41:62. The resulting predicted
ECAS-B score is therefore 111.60 with a residual
(i.e. ECAS-B minus predicted ECAS-B) of 15.2.
These values are the entered into the equation
ðXX^Þ
SEE
¼ ð96 111:60Þ
6:23 ¼ 2:44 which is less than
1.645). Therefore the patient’s score was signifi-
cantly lower than predicted. Furthermore, the
residual of 15.2 falls below the simple regression-
based threshold of 10.24. The multiple regression-
based method includes the variable education,
here 10.5 years, with the equation
Table 4. Multiple regression models to predict ECAS performance.
R2 SEE C (ECAS-A) (Education) X  X^
Predicting ECAS-B from ECAS-A
ALS Specific .451 5.01 28.82 .573 .587  8.24
ALS Non-Specific .297 2.25 15.31 .490 –  3.70
ECAS Total .483 5.97 37.94 .599 .628  9.82
R2 SEE C (ECAS-B) (Education) X  X^
Predicting ECAS-C from ECAS-B
ALS Specific .700 5.30 34.18 .938 –  8.72
ALS Non-Specific .431 1.87 12.69 .472 .243  3.08
ECAS Total .741 6.12 14.78 .872 –  10.07
R2 SEE C (ECAS-A) (ECAS-B) X  X^
Predicting ECAS-C from ECAS-A AND ECAS-B
ALS Specific .744 4.81 1.28 .583 .432  7.91
ALS Non-Specific .762 1.51 7.37 .473 .289  2.48
ECAS Total .815 5.11 2.74 .563 .416  8.41
R2 SEE C (ECAS-A) (ECAS-B) (Age) X  X^
ECAS-C performance from ECAS-A, ECAS-B, and age
ALS Non-Specific .665 1.42 10.91 .473 .269 .044  2.34
R2 is the multiple R2 when model contains one predictor and adjusted R2 when model contains more than one predictor. SEE is the
residual standard error, C is the intercept,  is the beta coefficient associated with the subscript, X  X^ is the residual (i.e. the difference
between the model predicted score and the observed score). The X  X^ column indicates the number of points difference required
between observed and estimated score to determine reliable difference – this is calculated as 1.645*(SEE).
6 C. Crockford et al.
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X^ ¼ AXA þ EdXEd þ C. The patient’s predicted
score is then X^ ¼ :599ð Þ 108ð Þ þ :628ð Þ 10:5ð Þ þ 37:94
which results in a predicted ECAS-B score of
109.23. Using the same equation as above,
ðXX^Þ
SEE
¼ ð96 109:23Þ
5:97 ¼ 2:22. Again, this falls outside
of 1.645, and the residual (13.23) is less than the
threshold of 9.82. Therefore, under all measures,
the patient presents with a significant and reliable
decrease in cognitive functioning.
Discussion
The monitoring of cognitive and behavioural symp-
toms longitudinally in ALS is integral to measure-
ment of progression of disease, outcome of clinical
trials and in providing person-centred care. While
the recent development of alternate forms of the
Edinburgh Cognitive and Behavioural ALS Screen
(ECAS) provided tools necessary to assess neuro-
psychological functioning over time, the present
paper aimed to provide data necessary for individ-
ual-level interpretation. Moreover, thresholds for
significant decline or improvement provide viable
end-points for clinical trials. An additional goal was
to explore the test-retest reliability of the ECAS’s
alternate forms when testing across clinically rele-
vant intervals. The present results demonstrate that
the alternate versions of the ECAS provide a
consistent method by which cognitive functioning
can be monitored over time in patients with ALS.
Building from the study by Crockford et al. (21), the
present study aimed to explore whether the alternate
forms of the ECAS ameliorate practice effects when
administered over clinically-meaningful testing
intervals. No significant practice effects were
observed for the ECAS-A, ECAS-B, and ECAS-C
when administered sequentially. The alternate forms
of the ECAS are successful in ameliorating practice,
thus confirming the findings of the authors (21).
The test-retest reliability of the alternate forms
was additionally explored. Intraclass correlation
coefficients (ICCs) were excellent for the composite
ALS Specific, ALS Non-Specific, and ECAS Total
scores. The individual cognitive subtests of ECAS
performed well also, achieving ICC values greater
than .70. While the ICC values for the visuospatial
task appear quite low, this is in part due to the
dependency of the ICC calculation on between-
subjects variability. Because there is very little
between-subject variability in the visuospatial task,
the small differences present are exaggerated sug-
gesting a smaller test-retest reliability than is war-
ranted (27). However, as noted, the composite ALS
Specific, ALS Non-Specific, and ECAS Total reli-
ability was excellent. This is particularly pertinent
given the sensitivity of these domains in detecting
cognitive impairment against a full neuropsycho-
logical battery (13). As such, participants who were
administered the ECAS forms serially showed good
consistency and stability across testing sessions.
The primary aim of this paper was to establish
methods of interpreting reliable change for patients
with ALS. Four models were utilized, including two
reliable change indices (RCI) and two regression
based (RB) methods. These methods account for
slightly different factors that may influence perform-
ance change. The RCI thresholds for reliable change
are the minimum increase or decrease in perform-
ance necessary to be considered reliable. Both RCI
methods produced similar thresholds for all com-
parisons (i.e. ECAS-A to ECAS-B, ECAS-B to
ECAS-C, and ECAS-A to ECAS-C).
The RCI methods proposed by Jacobson and
Truax (25) and modified by Chelune et al. (26) were
developed on the assumption of repeated assessment
using the same version of a test. For instance, the
SEm in these authors’ studies is calculated using
the standard deviation and test-retest reliability of
the same instrument. This does not pose an issue
when one considers that the test-retest reliability
used in the present study is the intraclass correl-
ations between two ECAS forms. However, RCI
calculations traditionally use the standard deviation
of the instrument assuming equality of variation for
Time 1 and Time 2. Fortunately, the standard
deviations for ALS Specific, ALS Non-Specific, and
ECAS total across alternate forms were only trivially
different (e.g. for ECAS Total scores, the standard
deviations were 11.26, 11.38, and 11.87 for the
ECAS-A, ECAS-B, and ECAS-C, respectively). It
was not deemed necessary to use a measure of
shared variance in place of standard deviation.
With regard to the regression-based methods,
linear regression models provide predictive scores
for patients based on their baseline ECAS perform-
ance, or a combination of this and demographic
variables. The deviation from a patient’s predicted
score and their actual score is used to determine
whether a deviation constitutes a reliable difference.
By dividing the residual by the standard error of the
residual, one can determine if an individual’s
departure from their predicted performance is
within normal variation, i.e. variation due to meas-
urement error, practice effects, or regression to the
mean. While regression-based methods may be
more complicated to calculate, they may also pro-
vide more accurate predictions that take account of
important moderating variables such as education
level. However, some authors have argued that
regression-based methods are not necessarily super-
ior to RCI methods (e.g. (19)). Additionally,
regression-based methods do have their own limita-
tions. As noted by Crawford and Garthwaite (24),
the error associated with predicting follow-up per-
formance from baseline performance using regres-
sion based techniques will be larger at the extremes,
i.e. the residuals at the extremes are greater.
Therefore, caution should be paid to interpreting
Measuring reliable change in congnition using the ECAS 7
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change of patients who score poorly at baseline.
Because the sample herein is of healthy controls
while the target patient population would be
expected to score toward the lower extremes, further
research would be needed to clarify whether RCI
and regression-based thresholds need to be devel-
oped based on initial test performance. This may be
achieved by exploring these thresholds in a sample
of MND patients where cognitive deterioration is
not expected or found, for example in patients who
possess a slower disease progression.
An important caveat in utilizing these thresholds
is that the ECAS is a cognitive screening tool, and
not designed to replace full neuropsychological
assessment. While a patient’s test-retest perform-
ance may be reliably described as a decline using the
thresholds herein, such findings should be corrobo-
rated with specialist neuropsychological input.
In deciding which method to utilize for detecting
reliable change, a pragmatic approach is recom-
mended. For research purposes, the multiple regres-
sion-based methods may provide more specific
indicators of change. However, these regression-
based methods are relatively more technical and
complex to calculate. The ECAS was designed to be
accessible to non-specialist health care professionals,
and thus, the recommendation of regression-based
methods may compromise the clinical utility of the
ECAS. Given the similarity in scores across all four
methods and the ease with which RCI methods can
be included in a clinical environment, a conservative
application of change scores is recommended for
clinical purposes. Based on the most conservative JT
method, and to reduce the number of false-posi-
tives, a change of 8, 4, or 9 points is recom-
mended for a significant change in ALS Specific,
ALS Non-Specific, or ECAS Total score,
respectively.
Conclusions
Measuring the progression of cognitive symptoms in
ALS has important clinical implications. Cognitive
status can play an important role in how patients
engage with interventions, in how clinicians engage
with patients, and in what services may be appro-
priate. The alternate forms of the ECAS provide a
method by which cognitive symptoms can be moni-
tored over time. The present study built on this by
providing a means by which a patient’s change over
time can be reliably interpreted. Four models of
change indices were calculated. The reliable change
indices may be the method with the highest clinical
utility; however, regression based methods may play
a role in more detailed analysis or clinical research.
Additionally, the present study demonstrated that
the test-retest reliability of the ECAS and its
alternate forms is excellent for the ALS Specific,
ALS Non-Specific, and ECAS Total scores. This,
along with no evidence of significant practice effects,
suggests that the ECAS-A-B-C are stable, consist-
ent, and useful in monitoring ALS patients’ cogni-
tive performance over time.
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